AbbVie Inc (ABBV)vsIQVIA Holdings Inc (IQV)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
IQV
IQVIA Holdings Inc
$275.06
-1.43%
HEALTHCARE · Cap: $45.35B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 272% more annual revenue ($64.39B vs $17.31B). ABBV leads profitability with a 9.8% profit margin vs 8.1%. ABBV appears more attractively valued with a PEG of 0.54. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
IQV
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
+13.7%
Fair Value
$205.31
Current Price
$275.06
$69.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.17 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 59/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?